Recurrent Disease Recruiting Phase 2 Trials for Buparlisib (DB11666)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs